Literature DB >> 35933430

Stem cell-based therapy for human diseases.

Duc M Hoang1, Phuong T Pham2, Trung Q Bach3, Anh T L Ngo2, Quyen T Nguyen3, Trang T K Phan3, Giang H Nguyen3, Phuong T T Le3, Van T Hoang3, Nicholas R Forsyth4, Michael Heke5, Liem Thanh Nguyen3.   

Abstract

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.
© 2022. The Author(s).

Entities:  

Mesh:

Year:  2022        PMID: 35933430      PMCID: PMC9357075          DOI: 10.1038/s41392-022-01134-4

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  491 in total

1.  Embryonic stem cell trials for macular degeneration: a preliminary report.

Authors:  Steven D Schwartz; Jean-Pierre Hubschman; Gad Heilwell; Valentina Franco-Cardenas; Carolyn K Pan; Rosaleen M Ostrick; Edmund Mickunas; Roger Gay; Irina Klimanskaya; Robert Lanza
Journal:  Lancet       Date:  2012-01-24       Impact factor: 79.321

2.  Robust induction of retinal pigment epithelium cells from human induced pluripotent stem cells by inhibiting FGF/MAPK signaling.

Authors:  Takao Kuroda; Satoshi Ando; Yuriko Takeno; Akiyoshi Kishino; Toru Kimura
Journal:  Stem Cell Res       Date:  2019-07-25       Impact factor: 2.020

3.  Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.

Authors:  Kaijian Zhou; Shu Guo; Shuang Tong; Qiang Sun; Fei Li; Xiaowei Zhang; Ying Qiao; Guoxin Liang
Journal:  Stem Cells Dev       Date:  2018-09-01       Impact factor: 3.272

Review 4.  Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns.

Authors:  Said A Omar; Amal Abdul-Hafez; Sherif Ibrahim; Natasha Pillai; Mohammed Abdulmageed; Ranga Prasanth Thiruvenkataramani; Tarek Mohamed; Burra V Madhukar; Bruce D Uhal
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

5.  Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics.

Authors:  Jozef Bartunek; Atta Behfar; Dariouch Dolatabadi; Marc Vanderheyden; Miodrag Ostojic; Jo Dens; Badih El Nakadi; Marko Banovic; Branko Beleslin; Mathias Vrolix; Victor Legrand; Christian Vrints; Jean Louis Vanoverschelde; Ruben Crespo-Diaz; Christian Homsy; Michal Tendera; Scott Waldman; William Wijns; Andre Terzic
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

6.  [Isolation of mononuclear cells from the bone marrow of patients with hemoblastoses using one-step ficoll-verographin density gradient separation].

Authors:  S V Pavlushina; T G Orlova; D Z Tabagari
Journal:  Eksp Onkol       Date:  1984

7.  Type 2 Alveolar Epithelial Cells Differentiated from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Mouse Pulmonary Fibrosis Through β-Catenin-Regulated Cell Apoptosis.

Authors:  Jiang Liu; Danyi Peng; Jingyi You; Ou Zhou; Huijun Qiu; Chang Hao; Hong Chen; Zhou Fu; Lin Zou
Journal:  Stem Cells Dev       Date:  2021-06-01       Impact factor: 3.272

8.  Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study.

Authors:  Phuong Le Thi Bich; Ha Nguyen Thi; Hoang Dang Ngo Chau; Tien Phan Van; Quyet Do; Hung Dong Khac; Dong Le Van; Luc Nguyen Huy; Khan Mai Cong; Thang Ta Ba; Trung Do Minh; Ngoc Vu Bich; Nhat Truong Chau; Phuc Van Pham
Journal:  Stem Cell Res Ther       Date:  2020-02-13       Impact factor: 6.832

9.  Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study.

Authors:  Abbas Ali Qayyum; Anders Bruun Mathiasen; Naja Dam Mygind; Jørgen Tobias Kühl; Erik Jørgensen; Steffen Helqvist; Jens Jørgen Elberg; Klaus Fuglsang Kofoed; Niels Groove Vejlstrup; Anne Fischer-Nielsen; Mandana Haack-Sørensen; Annette Ekblond; Jens Kastrup
Journal:  Stem Cells Int       Date:  2017-12-03       Impact factor: 5.443

View more
  1 in total

1.  Cultivation of Cryopreserved Human Dental Pulp Stem Cells-A New Approach to Maintaining Dental Pulp Tissue.

Authors:  Wang Wang; Ming Yan; Ghazal Aarabi; Ulrike Peters; Marcus Freytag; Martin Gosau; Ralf Smeets; Thomas Beikler
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.